SIGA Technologies Inc.
SIGA Technologies is a commercial-stage pharmaceutical company focused on health security markets in the US. Its lead product is TPOXX, an oral antiviral drug for treating human smallpox disease caused by variola virus. The company was founded in 1995 and is headquartered in New York City.
Overview
Strengths
- With an appreciation Potential of 188.57%, based on our fundamental analysis, it suggests the stock may be undervalued.
- Current Price to Earnings Ratio (5.86) is lower than the sector mean (289.29).
- Price to book ratio (2.03) is lower than the sector mean (733.70).
- The company has low debt. Net Debt to EBITDA Ratio is -0.50 and it is lower than the sector mean.
- The company has high returns. ROIC (31.07%) is higher than the sector mean (14.71%).
- EV/EBITDA (4.24) is lower than the sector mean (51.86).
- EV/EBIT (4.27) is lower than the sector mean.
- Price to free cash flow (4.21) is lower than the sector mean.
- Strong EBITDA Margin of 60.15%.
Weaknesses
- No significant weaknesses identified based on the analyzed metrics.
Key Financial Data
| Indicator | Value |
|---|
| PER | 10.8 |
| EV/EBITDA | 6.8 |
| Price/Free Cash Flow' | 13.1 |
| ROIC | 22.5% |
| Net Debt/EBITDA | -2.2 |